{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:57:17Z","timestamp":1790773037049,"version":"4.1.0"},"reference-count":24,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2015,6]]},"abstract":"ABSTRACT<\/jats:title>\n \n Arbekacin is a broad-spectrum aminoglycoside licensed for systemic use in Japan and under clinical development as an inhalation solution in the United States. We evaluated the occurrence of organisms isolated from pneumonias in U.S. hospitalized patients (PHP), including ventilator-associated pneumonia (VAP), and the\n in vitro<\/jats:italic>\n activity of arbekacin. Organism frequency was evaluated from a collection of 2,203 bacterial isolates (339 from VAP) consecutively collected from 25 medical centers in 2012 through the SENTRY Antimicrobial Surveillance Program. Arbekacin activity was tested against 904 isolates from PHP collected in 2012 from 62 U.S. medical centers and 303 multidrug-resistant (MDR) organisms collected worldwide in 2009 and 2010 from various infection types. Susceptibility to arbekacin and comparator agents was evaluated by the reference broth microdilution method. The four most common organisms from PHP were\n Staphylococcus aureus<\/jats:named-content>\n ,\n Pseudomonas aeruginosa<\/jats:named-content>\n ,\n Klebsiella<\/jats:named-content>\n spp., and\n Enterobacter<\/jats:named-content>\n spp. The highest arbekacin MIC among\n S. aureus<\/jats:named-content>\n isolates from PHP (43% methicillin-resistant\n S. aureus<\/jats:named-content>\n [MRSA]) was 4 \u03bcg\/ml. Among\n P. aeruginosa<\/jats:named-content>\n isolates from PHP, only one had an arbekacin MIC of >16 \u03bcg\/ml (MIC\n 50<\/jats:sub>\n and MIC\n 90<\/jats:sub>\n , 1 and 4 \u03bcg\/ml), and susceptibility rates for gentamicin, tobramycin, and amikacin were 88.0, 90.0, and 98.0%, respectively. Arbekacin (MIC\n 50<\/jats:sub>\n , 2 \u03bcg\/ml) and tobramycin (MIC\n 50<\/jats:sub>\n , 4 \u03bcg\/ml) were the most potent aminoglycosides tested against\n Acinetobacter baumannii<\/jats:named-content>\n . Against\n Enterobacteriaceae<\/jats:named-content>\n from PHP, arbekacin and gentamicin (MIC\n 50<\/jats:sub>\n and MIC\n 90<\/jats:sub>\n , 0.25 to 1 and 1 to 8 \u03bcg\/ml for both compounds) were generally more potent than tobramycin (MIC\n 50<\/jats:sub>\n and MIC\n 90<\/jats:sub>\n , 0.25 to 2 and 1 to 32 \u03bcg\/ml) and amikacin (MIC\n 50<\/jats:sub>\n and MIC\n 90<\/jats:sub>\n , 1 to 2 and 2 to 32 \u03bcg\/ml). Arbekacin also demonstrated potent\n in vitro<\/jats:italic>\n activity against a worldwide collection of well-characterized MDR Gram-negative and MRSA strains.\n <\/jats:p>","DOI":"10.1128\/aac.04839-14","type":"journal-article","created":{"date-parts":[[2015,3,24]],"date-time":"2015-03-24T02:32:47Z","timestamp":1427164367000},"page":"3263-3270","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":37,"title":["Arbekacin Activity against Contemporary Clinical Bacteria Isolated from Patients Hospitalized with Pneumonia"],"prefix":"10.1128","volume":"59","author":[{"given":"Helio S.","family":"Sader","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Rhomberg","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Farrell","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"349","article-title":"Antibacterial activities of arbekacin, a new aminoglycoside antibiotic, against methicillin-cephem-resistant Staphylococcus aureus","volume":"40","author":"Watanabe T","year":"1987","unstructured":"Watanabe T, Goi H, Hara T, Sugano T, Tanaka Y, Kazuno Y, Matsuhashi Y, Yamamoto H, Yokota T. 1987. Antibacterial activities of arbekacin, a new aminoglycoside antibiotic, against methicillin-cephem-resistant Staphylococcus aureus. Jpn J Antibiot 40:349\u2013356.","journal-title":"Jpn J Antibiot"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.3947\/ic.2013.45.1.62"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-012-0519-z"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.4.727"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-011-0262-x"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-014-2192-x"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01173-09"},{"key":"e_1_3_2_9_2","unstructured":"Ouchi S Aoki M Kamiyabu S Vutikullird A Gorfried M Ishihama T. 2014. Safety tolerability systemic and pulmonary pharmacokinetics of ME100 inhalation solution in healthy volunteers. Abstr 54th Intersci Conf Antimicrob Agents Chemother September 5 to 9 2014 Washington DC. http:\/\/www.icaac.org\/."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2014.05.007"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-012-0397-4"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.01.007"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02252-12"},{"key":"e_1_3_2_14_2","volume-title":"Approved standard","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 9th ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"9"},{"key":"e_1_3_2_15_2","volume-title":"Performance standards for antimicrobial susceptibility testing, 24th informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2014","unstructured":"Clinical and Laboratory Standards Institute. 2014. M100-S24. Performance standards for antimicrobial susceptibility testing, 24th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_16_2","unstructured":"EUCAST. 2014. Breakpoint tables for interpretation of MICs and zone diameters. Version 4.0. http:\/\/www.eucast.org\/clinical_breakpoints\/. Accessed 15 January 2014."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200405-644ST"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1086\/653053"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-008-1336-9"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201311-395FR"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm385"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201011-1894OC"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2008.05.016"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1586\/eri.09.108"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.01556"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.04839-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.04839-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:07:44Z","timestamp":1645484864000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.04839-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1128\/AAC.04839-14"],"URL":"https:\/\/doi.org\/10.1128\/aac.04839-14","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"2014-11-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-03-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-05-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}